TW202342096A - 靶向dll3的癌症治療 - Google Patents

靶向dll3的癌症治療 Download PDF

Info

Publication number
TW202342096A
TW202342096A TW112106776A TW112106776A TW202342096A TW 202342096 A TW202342096 A TW 202342096A TW 112106776 A TW112106776 A TW 112106776A TW 112106776 A TW112106776 A TW 112106776A TW 202342096 A TW202342096 A TW 202342096A
Authority
TW
Taiwan
Prior art keywords
dll3
agent
dose
administered
day
Prior art date
Application number
TW112106776A
Other languages
English (en)
Chinese (zh)
Inventor
紗卓尹 諾欣 哈雪米
牧可 密諾察
雅曼達 葛瑞克
曦 陳
蜜拉 琪絲樂
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202342096A publication Critical patent/TW202342096A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112106776A 2022-02-23 2023-02-23 靶向dll3的癌症治療 TW202342096A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263313119P 2022-02-23 2022-02-23
US63/313,119 2022-02-23
US202263429311P 2022-12-01 2022-12-01
US63/429,311 2022-12-01

Publications (1)

Publication Number Publication Date
TW202342096A true TW202342096A (zh) 2023-11-01

Family

ID=85724660

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112106776A TW202342096A (zh) 2022-02-23 2023-02-23 靶向dll3的癌症治療

Country Status (12)

Country Link
US (1) US20250154247A1 (https=)
EP (1) EP4482586A1 (https=)
JP (1) JP2025508786A (https=)
KR (1) KR20240153575A (https=)
AU (1) AU2023224210A1 (https=)
CA (1) CA3252459A1 (https=)
CL (1) CL2024002529A1 (https=)
IL (1) IL314195A (https=)
JO (1) JOP20240188A1 (https=)
MX (1) MX2024010330A (https=)
TW (1) TW202342096A (https=)
WO (1) WO2023164474A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080688A1 (en) * 2023-10-12 2025-04-17 Amgen Inc. Compositions of bispecific antibody constructs to human dll3 and human cd3
TW202602488A (zh) * 2024-03-11 2026-01-16 美商安進公司 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026075950A1 (en) * 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2018002166A (es) * 2015-08-20 2018-09-12 Abbvie Stemcentrx Llc Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
US11976133B2 (en) 2020-01-31 2024-05-07 Gensun Biopharma Inc. Bispecific T cell engagers
CR20220541A (es) 2020-03-31 2022-11-28 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
IL307646A (en) * 2021-05-10 2023-12-01 Amgen Inc Dosing regimen for combination therapy targeting DLL3 and PD-1

Also Published As

Publication number Publication date
IL314195A (en) 2024-09-01
US20250154247A1 (en) 2025-05-15
CA3252459A1 (en) 2023-08-31
CL2024002529A1 (es) 2025-01-24
EP4482586A1 (en) 2025-01-01
JOP20240188A1 (ar) 2024-08-19
KR20240153575A (ko) 2024-10-23
WO2023164474A1 (en) 2023-08-31
MX2024010330A (es) 2024-08-30
AU2023224210A1 (en) 2024-07-18
JP2025508786A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
US11866509B2 (en) Humanized antibodies against CEACAM1
US20240317856A1 (en) Dosing regimen for combination therapy targeting dll3 and pd-1
TW202342096A (zh) 靶向dll3的癌症治療
US11591395B2 (en) Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
KR20220097470A (ko) 항-dll3 작용제의 투여 요법
US20230074793A1 (en) Treatment with a bispecific antibody that binds ctla4 and pd1
CA3136892A1 (en) Methods of treating renal cancer with an anti- psma/cd3 antibody
KR20240028452A (ko) 암을 치료하기 위한 방법 및 조성물
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
CN118785922A (zh) 靶向dll3的癌症治疗
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
TW202436335A (zh) 治療表現ｄｌｌ３的癌症之方法
WO2024102645A1 (en) Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer
TW202612729A (zh) 涉及抗ｈｌａ－ｇ抗體及抗ｅｇｆｒ抗體以及抗ｐｄ－１抗體之組合療法
HK40112915A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
HK40110052A (zh) 用於治疗癌症的方法和组合物
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
WO2020135415A1 (zh) 抗pd-l1单克隆抗体治疗癌症的用途